NCT01160237View on ClinicalTrials.gov

Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM

PHASE3TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

PandemrixTM

One dose intramuscular injection

BIOLOGICAL

FluarixTM/ Influsplit SSW® 2010/2011

One dose intramuscular injection

Trial Locations (5)

47574

GSK Investigational Site, Goch

55131

GSK Investigational Site, Mainz

72074

GSK Investigational Site, Tübingen

97070

GSK Investigational Site, Würzburg

04103

GSK Investigational Site, Leipzig

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01160237 - Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM | Biotech Hunter | Biotech Hunter